Skip to content
Our Company
Overview
Leadership Team
Pipeline & Programs
Peripherally-acting CB1 Inverse Agonists Pipeline
Monlunabant
INV-300 Series and INV-347
INV-101
Other Possible Indications
Our Approach
Peripheral CB1r Blockade
The Endocannabinoid System
References
News & Events
FR
EN
Menu
Home
Our Company
Overview
Leadership Team
Pipeline & Programs
Peripherally-acting CB1 Inverse Agonists Pipeline
Monlunabant
INV-300 Series and INV-347
INV-101
Other Possible Indications
Our Approach
Peripheral CB1r Blockade
The Endocannabinoid System
References
News & Events
1000km Challenge
Terms and Conditions
Privacy Policy
News
& Events
News
& Events
Latest
releases
National Institutes of Health Notice on Prospective Grant of Exclusive License.
